Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Effect of imatinib mesylate and growth in pediatric CML: A systematic review and meta-analysis (J Pediatr Hematol Oncol, July 2023)

Effect of imatinib mesylate on growth in pediatric CML: A systematic review and meta-analysis
Gupta P et al. J Pediatr Hematol Oncol, July 2023

 

 

 

Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults (Mersin S et al. Expert Opin Pharmacother, July 2023)

Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults
Mersin S et al. Expert Opin Pharmacother, July 2023 (epub ahead of print)

 

 

 

Pediatric chronic myeloid leukemia in myeloid blast crisis (Dey B and Dutta A. Autpos Case Rep, April 2023)

Pediatric chronic myeloid leukemia in myeloid blast crisis
Dey B and Dutta A. Autpos Case Rep, April 2023 – open access publication

 

 

 

Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase CML in the tyrosine kinase inhibitor era (Ishida H et al. Am J Hematol, May 2023)

Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase CML in the tyrosine kinase inhibitor era
Ishida H et al. Am J Hematol, May 2023 (epub ahed of print)

 

 

 

Recent progress in the management of pediatric chronic myeloid leukemia - Review (Shima H. and Shimada H. Int J Hematol, February 2023)

Recent progress in the management of pediatric chronic myeloid leukemia
Shima H & Shimada H. Int J Hematol, February 2023 – open access publication

 

 

 

  1. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations - Review (Sembill S et al. Leukemia, January 2023)
  2. Impact of tyrosine kinase inhibitors applied for first-line chronic myeloid leukemia treatment on platelet function in whole blood of healthy volunteers in vitro (Eckart F et al. Hamostaseologie, January 2023)
  3. Children with chronic myeloid leukemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicentre experience in Taiwan (Liu HC et al. Br J Cancer, January 2023)
  4. Relative bioavailability and food effect of asciminib pediatric mini-tablet formulation compared to the reference tablet formulation in healthy adult participants (Hoch M et al. Clin Pharmacol Drug Dev, January 2023)